- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Clinical Trials
- October 2025
- 128 Pages
Global
From €3099EUR$3,450USD£2,647GBP
- Report
- November 2025
- 474 Pages
Global
From €6422EUR$7,150USD£5,486GBP
- Report
- September 2025
- 344 Pages
Global
From €4446EUR$4,950USD£3,798GBP
- Report
- May 2026
- 141 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
- Report
- April 2026
- 136 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- August 2026
- 186 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- April 2026
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- June 2026
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- April 2026
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- April 2026
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- February 2026
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- December 2025
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- August 2026
- 463 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- August 2026
- 174 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- August 2026
- 374 Pages
Global
From €5254EUR$5,850USD£4,488GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more